NEWS RELEASE
1818 Market Street, Suite 1600 • Philadelphia, PA 19107 • www.rtog.org • www.acr.org
Dr. Bo Lu to Lead the Radiation Therapy Oncology Group’s Lung Cancer Translational Research
Program
The Radiation Therapy Oncology Group (RTOG) announced that Bo Lu, M.D., Ph.D., of Thomas Jefferson University, has
been appointed chair of the group’s Translational Research Program (TRP) Committee’s Lung Cancer Subcommittee.
The RTOG TRP Committee supports the integration of new scientific discoveries into the design of multi-center clinical
trials.
Dr. Lu is professor in the Department of Radiation Oncology at Jefferson (Philadelphia, PA) where he also serves as
director of the department’s Division of Molecular Radiation Biology. Prior to joining Jefferson in early 2011, Dr. Lu was
associate professor in the Departments of Radiation Oncology and Cancer Biology at Vanderbilt University School of
Medicine (Nashville, TN) and director of the Department of Radiation Oncology’s translational research program. He is
also a visiting professor of radiation oncology at Tianjin Medical University Cancer Hospital, in Tianjing, China.
“As a member of RTOG’s Translation Research Program Committee since 2009, it has been exciting to be part of
research efforts incorporating novel cancer treatment strategies into the design of early phase, multicenter clinical trials,”
says Dr. Lu. Among Dr. Lu’s basic science research interests are the development of drugs that cause tumor cells to be
more sensitive to radiation therapy and that target lung cancer stem cells.
“Dr. Lu is internationally renowned for his work in translational radiation oncology, and I am enthusiastic about his
leadership role with regard to guiding the RTOG’s translational research agenda in lung cancer,” says Adam Dicker,
M.D., Ph.D, Professor and Chairman of Radiation Oncology at Thomas Jefferson University and RTOG’s Translational
Research Program Chair. “He has demonstrated talent for applying findings from the laboratory into clinical research,”
remarks Dr. Dicker.
“Dr. Lu’s extensive basic science background and insight about promising new agents will be a tremendous asset to
RTOG’s Lung Cancer Committee,” says committee chair and radiation oncologist Jeffrey Bradley, M.D., Associate
Professor of Radiation Oncology at Washington School of Medicine (St. Louis, Mo). Dr. Bradley adds, “I anticipate an
exciting and productive collaboration.”
“The opportunity to work with RTOG colleagues to advance new treatment options and improve clinical care for lung
cancer patients is very rewarding,” says Dr. Lu, “and I am pleased to assume an expanded role within a research
organization that promotes the robust evaluation of new therapeutic approaches in radiation oncology.”
Dr. Lu received his Ph.D. in cell and molecular biology from Baylor School of Medicine (Houston, TX) and his doctorate in
medicine from Shanghai Medical University in China. He completed his residency in radiation oncology at the University of
Southern California. Dr. succeeds Quynh Le, M.D., Ph.D. from Stanford University who recently was named chair of
RTOG’s Head and Neck Cancer Committee.
For more information about RTOG and the group’s Translational Research Program: www.rtog.org